CORTEXA
← Browse
crossrefCancers2024-11-01Cited by 44

The Evolution of Artificial Intelligence in Medical Imaging: From Computer Science to Machine and Deep Learning

Michele Avanzo, Joseph Stancanello, Giovanni Pirrone, Annalisa Drigo, Alessandra Retico

Artificial intelligence (AI), the wide spectrum of technologies aiming to give machines or computers the ability to perform human-like cognitive functions, began in the 1940s with the first abstract models of intelligent machines. Soon after, in the 1950s and 1960s, machine learning algorithms such as neural networks and decision trees ignited significant enthusiasm. More recent advancements include the refinement of learning algorithms, the development of convolutional neural networks to efficiently analyze images, and methods to synthesize new images. This renewed enthusiasm was also due to the increase in computational power with graphical processing units and the availability of large digital databases to be mined by neural networks. AI soon began to be applied in medicine, first through expert systems designed to support the clinician’s decision and later with neural networks for the detection, classification, or segmentation of malignant lesions in medical images. A recent prospective clinical trial demonstrated the non-inferiority of AI alone compared with a double reading by two radiologists on screening mammography. Natural language processing, recurrent neural networks, transformers, and generative models have both improved the capabilities of making an automated reading of medical images and moved AI to new domains, including the text analysis of electronic health records, image self-labeling, and self-reporting. The availability of open-source and free libraries, as well as powerful computing resources, has greatly facilitated the adoption of deep learning by researchers and clinicians. Key concerns surrounding AI in healthcare include the need for clinical trials to demonstrate efficacy, the perception of AI tools as ‘black boxes’ that require greater interpretability and explainability, and ethical issues related to ensuring fairness and trustworthiness in AI systems. Thanks to its versatility and impressive results, AI is one of the most promising resources for frontier research and applications in medicine, in particular for oncological applications.

View free PDFSource page

Related papers

crossrefCancers2024-11-11Cited by 38

A Hybrid Deep Learning and Machine Learning Approach with Mobile-EfficientNet and Grey Wolf Optimizer for Lung and Colon Cancer Histopathology Classification

Raquel Ochoa-Ornelas, Alberto Gudiño-Ochoa, Julio Alberto García-Rodríguez

Background: Lung and colon cancers are among the most prevalent and lethal malignancies worldwide, underscoring the urgent need for advanced diagnostic methodologies. This study aims to develop a hybrid deep learning and machine learning framework for the classification of Colon…

View free PDFSource page
crossrefCancers2022-04-15Cited by 35

Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma

Catharina Silvia Lisson, Christoph Gerhard Lisson, Marc Fabian Mezger, Daniel Wolf, Stefan Andreas Schmidt, Wolfgang M. Thaiss, et al.

Mantle cell lymphoma (MCL) is a rare lymphoid malignancy with a poor prognosis characterised by frequent relapse and short durations of treatment response. Most patients present with aggressive disease, but there exist indolent subtypes without the need for immediate intervention…

View free PDFSource page
crossrefCancers2024-12-28Cited by 4

Machine Learning and Computed Tomography Radiomics to Predict Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer: A Pilot Study

Ian Janzen, Cheryl Ho, Barbara Melosky, Qian Ye, Jessica Li, Gang Wang, et al.

Background/Objectives: Pembrolizumab monotherapy is approved in Canada for first-line treatment of advanced NSCLC with PD-L1 ≥ 50% and no EGFR/ALK aberrations. However, approximately 55% of these patients do not respond to pembrolizumab, underscoring the need for the early interv…

View free PDFSource page
crossrefCancers2023-06-15Cited by 22

A Weakly Supervised Deep Learning Model and Human–Machine Fusion for Accurate Grading of Renal Cell Carcinoma from Histopathology Slides

Qingyuan Zheng, Rui Yang, Huazhen Xu, Junjie Fan, Panpan Jiao, Xinmiao Ni, et al.

(1) Background: The Fuhrman grading (FG) system is widely used in the management of clear cell renal cell carcinoma (ccRCC). However, it is affected by observer variability and irreproducibility in clinical practice. We aimed to use a deep learning multi-class model called SSL-CL…

View free PDFSource page
crossrefCancers2025-02-19Cited by 21

The Evolution of Anticancer 3D In Vitro Models: The Potential Role of Machine Learning and AI in the Next Generation of Animal-Free Experiments

Carolina Momoli, Beatrice Costa, Lorenzo Lenti, Matilde Tubertini, Marco Parenti, Elisa Martella, et al.

The development of anticancer therapies has increasingly relied on advanced 3D in vitro models, which more accurately mimic the tumor microenvironment compared to traditional 2D cultures. This review describes the evolution of these 3D models, highlighting significant advancement…

View free PDFSource page
crossrefCancers2026-03-11

Unlocking Tumor Aggressiveness in Endometrial Cancer: AI-Driven PET/CT Radiomics and Machine Learning for Prediction of High-Risk Tumor Histology

Samet Yagci, Evrim Erdemoglu, Mehmet Erdogan, Mustafa Avci, Ahmet Tunc, Ismail Ozkoc, et al.

Purpose: Accurate preoperative risk stratification in endometrial cancer (EC) is essential for guiding surgical and therapeutic decisions. This study aimed to evaluate the discriminative performance of [18F]-FDG PET/CT-derived radiomic features combined with machine learning mode…

View free PDFSource page